Kenvue Inc. (NYSE:KVUE) Shares Sold by Childress Capital Advisors LLC

Childress Capital Advisors LLC reduced its stake in Kenvue Inc. (NYSE:KVUE) by 5.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,188 shares of the company’s stock after selling 902 shares during the period. Childress Capital Advisors LLC’s holdings in Kenvue were worth $364,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in KVUE. Norges Bank bought a new stake in shares of Kenvue in the 4th quarter worth approximately $521,348,000. Starboard Value LP bought a new stake in shares of Kenvue in the 4th quarter worth approximately $467,864,000. Franklin Resources Inc. raised its holdings in shares of Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock worth $912,059,000 after purchasing an additional 16,269,721 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Kenvue by 12.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock worth $2,085,070,000 after purchasing an additional 10,682,003 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Kenvue by 3.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company’s stock worth $5,249,665,000 after purchasing an additional 8,211,748 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

NYSE KVUE opened at $21.39 on Friday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. The company has a fifty day simple moving average of $22.99 and a 200 day simple moving average of $22.41. The company has a market cap of $41.03 billion, a P/E ratio of 38.88, a P/E/G ratio of 3.32 and a beta of 0.98. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $25.17.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. The business had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. Kenvue’s quarterly revenue was down 3.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.28 EPS. On average, sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.83%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Redburn Atlantic assumed coverage on shares of Kenvue in a report on Thursday, April 10th. They set a “neutral” rating and a $23.50 price target on the stock. UBS Group boosted their price target on shares of Kenvue from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Friday, May 9th. Citigroup reiterated a “neutral” rating on shares of Kenvue in a research note on Friday, June 13th. Barclays upped their price objective on shares of Kenvue from $22.00 to $23.00 and gave the company an “equal weight” rating in a research note on Monday, May 12th. Finally, Piper Sandler boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.